Ticker
ABVC

Price
0.72
Stock movement up
+0.02 (2.40%)
Company name
ABVC Biopharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
23.50M
Ent værdi
26.96M
Pris/omsætning
68.50
Pris/bog
4.13
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-70.97%
3 års afkast
-52.57%
5 års afkast
-87.58%
10 års afkast
-
Senest opdateret: 2023-02-06

UDBYTTE

ABVC betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning68.50
Pris til egenkapital4.13
EV i forhold til salg78.60

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier32.63M
EPS (TTM)-0.60
FCF pr. aktie (TTM)-0.28

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)343.00K
Bruttofortjeneste (TTM)319.19K
Driftsindkomst (TTM)-18.43M
Nettoindkomst (TTM)-19.49M
EPS (TTM)-0.60
EPS (1 år frem)-0.36

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)93.06%
Driftsmargin (TTM)-5372.83%
Fortjenstmargin (TTM)-5682.74%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter1.32M
Nettotilgodehavender547.68K
Omsætningsaktiver i alt2.90M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver10.48M
Kreditor0.00
Kortfristet/nuværende langsigtet gæld3.11M
Summen af kortfristede forpligtelser3.89M
Sum gæld4.79M
Aktionærernes egenkapital5.69M
Materielle nettoaktiver5.92M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-8.99M
Investeringsudgifter (TTM)212.82K
Fri pengestrøm (TTM)-9.02M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-342.37%
Afkast af aktiver-185.98%
Afkast af investeret kapital-246.01%
Kontant afkast af investeret kapital-113.84%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning0.71
Daglig høj0.73
Daglig lav0.71
Daglig volumen27K
Højeste gennem alle tider716331.21
1 års analytiker estimat9.50
Beta0.28
EPS (TTM)-0.60
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation29 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABVCS&P500
Nuværende prisfald fra top notering-100.00%-14.21%
Højeste prisfald-100.00%-56.47%
Højeste efterår dato6 Feb 20239 Mar 2009
Gennemsnitlig fald fra toppen-91.23%-11.49%
Gennemsnitlig tid til nyt højdepunkt119 days13 days
Maks. tid til nyt højdepunkt1729 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ABVC (ABVC Biopharma Inc) company logo
Markedsværdi
23.50M
Markedsværdi kategori
Small-cap
Beskrivelse
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Personale
28
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
19. januar 2023
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Several potential paths to near-term milestones… ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies fo...
18. januar 2023
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
5. januar 2023
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Adding venues and enrolling patients to advance assets … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing ther...
20. december 2022
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
17. november 2022
ABVC BioPharma ( NASDAQ:ABVC ) Third Quarter 2022 Results Key Financial Results Net loss: US$3.70m (loss widened by...
17. november 2022
FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
14. november 2022
FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
7. november 2022
FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
2. november 2022
FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
5. oktober 2022
Næste side